<code id='8FEF833DED'></code><style id='8FEF833DED'></style>
    • <acronym id='8FEF833DED'></acronym>
      <center id='8FEF833DED'><center id='8FEF833DED'><tfoot id='8FEF833DED'></tfoot></center><abbr id='8FEF833DED'><dir id='8FEF833DED'><tfoot id='8FEF833DED'></tfoot><noframes id='8FEF833DED'>

    • <optgroup id='8FEF833DED'><strike id='8FEF833DED'><sup id='8FEF833DED'></sup></strike><code id='8FEF833DED'></code></optgroup>
        1. <b id='8FEF833DED'><label id='8FEF833DED'><select id='8FEF833DED'><dt id='8FEF833DED'><span id='8FEF833DED'></span></dt></select></label></b><u id='8FEF833DED'></u>
          <i id='8FEF833DED'><strike id='8FEF833DED'><tt id='8FEF833DED'><pre id='8FEF833DED'></pre></tt></strike></i>

          entertainment

          entertainment

          author:Wikipedia    Page View:554
          The profit margin at Optum Health is at the lowest in a decade. Courtesy United

          Just weeks after the division of UnitedHealth Group that provides care to patients posted its lowest profit margin in a decade, the company has shuffled around several top executives.

          Amar Desai is now CEO of Optum Health, according to a July LinkedIn post. Optum Health encompasses UnitedHealth’s physician practices, surgery centers, urgent care clinics, and other providers. Desai took over for Wyatt Decker, who moved into the role of chief physician overseeing “value-based care” across all of UnitedHealth.

          advertisement

          Heather Cianfrocco also became the president of Optum, a separate LinkedIn post from last week shows. That makes her one of the most powerful people overseeing all aspects of Optum. She most recently was CEO of Optum Rx, UnitedHealth’s pharmacy benefit manager, one of the largest in the country. Patrick Conway, a former top Medicare official in the Obama administration and former head of Blue Cross Blue Shield of North Carolina, is now the CEO of Optum Rx.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more
          Doctors' information doesn't help them choose wisely when sick
          Doctors' information doesn't help them choose wisely when sick

          AdobeDoctorsarefullofadvice:Eathealthy.Exercise.Don’tmissyourmedications.Don’tgetthatunnecessarytest

          read more
          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more

          Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

          YichuanCao/SipaUSAGileadSciencessaidMondayitwillacquireCymaBayTherapeuticsfor$4.3billion,addinganewt